Physician profile
Daniel J Flaherty
NPI 1386602449
$652.13
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.83 · 2020: $56.10 · 2021: $138 · 2022: $192 · 2023: $134 · 2024: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $240.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $150.58 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Grifols USA, LLC | $106.38 | 2021-2024 | Prolastin-C Liquid |
| Abbvie INC. | $65.36 | 2019-2023 | |
| Allergan, INC. | $46.96 | 2020-2021 | |
| Daiichi Sankyo INC. | $35.64 | 2021-2024 | Injectafer |
| Astellas Pharma US INC | $33.70 | 2023-2024 | Myrbetriq, Veozah |
| Amgen INC. | $27.80 | 2020-2024 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.97 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.02 | 2019-2022 | |
| Amarin Pharma, INC. | $22.84 | 2021-2022 | |
| Axsome Therapeutics, INC. | $19.09 | 2022 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Exact Sciences Corporation | $15.50 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $13.33 | 2022 | |
| Medtronic, INC. | $12.87 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12.42 | 2021 | |
| Eisai INC. | $12.34 | 2020 | |
| Merck Sharp & Dohme LLC | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.